This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
ELISA/assay
product name :
Human Kallikrein 3/PSA Quantikine ELISA Kit
catalog :
DKK300
quantity :
1 Kit
price :
655 USD
citations: 18
Reference
Hagemann U, Schatz C, Suominen M, Schlicker A, Knuuttila M, Wilson T, et al. Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models. Int J Mol Sci. 2024;25: pubmed publisher
Suominen M, Knuuttila M, Schatz C, Schlicker A, V xe4 xe4 r xe4 niemi J, Sj xf6 holm B, et al. Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. Int J Mol Sci. 2023;24: pubmed publisher
Cole R, Chen W, Pascal L, Nelson J, Wipf P, Wang Z. (+)-JJ-74-138 is a Novel Noncompetitive Androgen Receptor Antagonist. Mol Cancer Ther. 2022;21:483-492 pubmed publisher
Case T, Merkel A, Ramírez Solano M, Liu Q, Sterling J, Jin R. Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer. Transl Oncol. 2021;14:101213 pubmed publisher
Mao C, Wang S, Su Y, Tseng S, He L, Wu A, et al. Protein detection in blood with single-molecule imaging. Sci Adv. 2021;7: pubmed publisher
D Souza A, Chevillet J, Ghanouni P, Yan X, Tewari M, Gambhir S. Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence. PLoS ONE. 2018;13:e0194268 pubmed publisher
Suominen M, Fagerlund K, Rissanen J, Konkol Y, Morko J, Peng Z, et al. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res. 2017;23:4335-4346 pubmed publisher
Sanna V, Singh C, Jashari R, Adhami V, Chamcheu J, Rady I, et al. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy. Sci Rep. 2017;7:41573 pubmed publisher
Jarrard D, Konety B, Huang W, Downs T, Kolesar J, Kim K, et al. Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. Am J Clin Exp Urol. 2016;4:17-27 pubmed
Eswaraka J, Giddabasappa A, Han G, Lalwani K, Eisele K, Feng Z, et al. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer. BMC Cancer. 2014;14:742 pubmed publisher
Windus L, Kiss D, Glover T, Avery V. In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer. Exp Cell Res. 2012;318:2507-19 pubmed publisher
Squillace R, Miller D, Wardwell S, Wang F, Clackson T, Rivera V. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012;41:425-32 pubmed publisher
Colquhoun A, Venier N, Vandersluis A, Besla R, Sugar L, Kiss A, et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012;15:346-52 pubmed publisher
Darmanis S, Nong R, Hammond M, Gu J, Alderborn A, Vänelid J, et al. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol Cell Proteomics. 2010;9:327-35 pubmed publisher
Stan S, Singh S. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells. Clin Cancer Res. 2009;15:4895-903 pubmed publisher
Kim S, Singh S. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther. 2009;8:1946-54 pubmed publisher
Russo A, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res. 2009;15:4292-8 pubmed publisher
Deep G, Oberlies N, Kroll D, Agarwal R. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene. 2008;27:3986-98 pubmed publisher
product information
master code :
DKK300
SKU :
DKK300
product name :
Human Kallikrein 3/PSA Quantikine ELISA Kit
unit size :
1 Kit
description :
The Human Kallikrein 3/PSA Quantikine ELISA Kit from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human Kallikrein 3/PSA in cell culture supernates (50 ul), serum (50 ul), edta plasma (50 ul), heparin plasma (50 ul).
target :
Kallikrein 3/PSA
category :
ELISAs
species :
Human
specificity :
Natural and recombinant human KLK3/PSA
gene symbol :
KLK3
kit type :
Solid Phase Sandwich ELISA
assay length :
4.5 hours
elisaSampleTypes :
Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)
elisaSensitivity :
0.069 ng/mL
elisaRange :
0.94 - 60 ng/mL
top caption :
Human Kallikrein 3/PSA ELISA Cell Culture Supernate Standard Curve
applications :
ELISA
USD :
655 USD
product details :
The Quantikine Human KLK3/PSA Immunoassay is a 4.5 hour solid phase immunoassay designed to measure KLK3/PSA in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human KLK3/PSA, and antibodies raised against the recombinant protein. Natural human KLK3/PSA showed dose-response curves that were parallel to the standard curves obtained using the recombinant Quantikine kit standards, indicating that this kit can be used to determine relative levels of natural human KLK3/PSA.
alt names :
APS seminin, EC 3.4.21, EC 3.4.21.77, Gamma-seminoprotein, hK3, kallikrein 3, (prostate specific antigen), Kallikrein-3, kallikrein-related peptidase 3, KLK2A1, KLK3, P-30 antigen, prostate specific antigen, prostate-specific antigen, PSA, PSA semenogelase, Semenogelase, Seminin
storage :
Store the unopened product at 2 - 8 ░C. Do not use past expiration date.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.